SCHEMBL5388625

SCHEMBL5388625

COc1cc([N+](=O)[O-])ccc1OCCN1CCCCC1C

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 2/20 0.52
▸ HTR2C P28335 2/20 0.49
▸ ALDH1A1 P00352 3/20 0.46
▸ MAPT P10636 3/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ CRHBP P24387 1/20 0.46
▸ CRHR2 Q13324 1/20 0.46
▸ LMNA P02545 3/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ MCHR1 Q99705 1/20 0.43
▸ HTR2A P28223 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5381743 0.97 HRH3 (0.56) HRH3HTR2CALDH1A1MAPTSMN1; SMN2
SCHEMBL6204091 0.88 ALDH1A1 (0.45) ALDH1A1MAPTSMN1; SMN2LMNANPC1
SCHEMBL5389879 0.85 SMN1; SMN2 (0.47) HTR2CALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL3870460 0.85 SMN1; SMN2 (0.47) HTR2CALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL3860546 0.83 MCHR1 (0.51) ALDH1A1MAPTSMN1; SMN2LMNANPC1
SCHEMBL3860554 0.83 MCHR1 (0.51) ALDH1A1MAPTSMN1; SMN2LMNANPC1
SCHEMBL5381533 0.83 MAPT (0.49) ALDH1A1MAPTSMN1; SMN2LMNANPC1
SCHEMBL264564 0.83 LTA4H (0.57) HRH3ALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL3863267 0.81 KDM4E (0.53) HTR2CALDH1A1MAPTSMN1; SMN2NPC1
SCHEMBL5381777 0.80 LTA4H (0.54) HRH3ALDH1A1MAPTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220777-B2 Lactam derivatives as antagonists for human 11cby receptors SMITHKLINE BEECHAM P.L.C. (GB) 2007-05-22 — — US disclosed
EP-1436267-B1 LACTAM DERIVATIVES AS ANTAGONISTS FOR HUMAN 11CBY RECEPTORS SMITHKLINE BEECHAM PLC (GB) 2006-12-27 — — EP disclosed
US-20060287321-A1 Novel Lactam Derivatives SMITHKLINE BEECHAM P.L.C. (GB) 2006-12-21 — — US disclosed
US-20050059651-A1 Lactam derivatives as antagonists for human 11cby receptors SMITHKLINE BEECHAM P.L.C. (GB) 2005-03-17 — — US disclosed
EP-1436267-A1 LACTAM DERIVATIVES AS ANTAGONISTS FOR HUMAN 11CBY RECEPTORS SMITHKLINE BEECHAM PLC (GB) 2004-07-14 — — EP disclosed
WO-2003033480-A1 LACTAM DERIVATIVES AS ANTAGONISTS FOR HUMAN 11CBY RECEPTORS SMITHKLINE BEECHAM PLC (GB) 2003-04-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059651-A1 Lactam derivatives as antagonists for human 11cby receptors ADRB3, GPR3, ADRB1 HRH3 714/4885HTR2C 434/4885ALDH1A1 2468/4885
US-20060287321-A1 Novel Lactam Derivatives MRPL21, PEPD, STS HRH3 3756/4885HTR2C 4610/4885ALDH1A1 2328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback